Eli Lilly's migraine treatment wins US FDA approval

Eli Lilly's migraine treatment wins US FDA approval

The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow.

The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the NYSE in New
FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid

REUTERS: The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow.

The drug, formerly called lasmiditan, has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults.

(Reporting by Shivani Singh; Editing by Shinjini Ganguli)

Source: Reuters

Bookmark